Center for Cancer Research
 CCR Home   About CCR   CCR Intranet       
        
 

LEC Home Cellular and Molecular Biology Section Chemical Carcinogensis Section Molecular Cytogenetics Section DNA Mini Core Facility Confocal Microscopy Core Facility Resources
   
  Research Goals
   
  Lab Picture
   
  Laboratory Chief
   
  Contact Information
   
  Lab Location
   
  Human Hepatocellular
Carcinoma Bibliography
   



Human Hepatocellular Carcinoma Bibliography

  1. Parkin,D.M. (1998). The global burden of cancer. Semin. Cancer Biol. 8, 219-235. NLM: 99086853

  2. Grisham,J.W. (1997). Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis 18, 59-81. NLM: 97207098

  3. Harris,C.C. and Sun,T. (1984). Multifactoral etiology of human liver cancer. Carcinogenesis 5, 697-701. NLM: 84205969

  4. El Serag,H.B. and Mason,A.C. (1999). Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750. NLM: 99156340

  5. Taylor-Robinson,S.D., Foster,G.R., Arora,S., Hargreaves,S., and Thomas,H.C. (1997). Increase in primary liver cancer in the UK, 1979-94. Lancet 350, 1142-1143. NLM: 98003106

  6. Benhamiche,A.M., Faivre,C., Minello,A., Clinard,F., Mitry,E., Hillon,P., and Faivre,J. (1998). Time trends and age-period-cohort effects on the incidence of primary liver cancer in a well-defined French population: 1976-1995. J. Hepatol. 29, 802-806. NLM: 99049665

  7. Unoura,M., Kaneko,S., Matsushita,E., Shimoda,A., Takeuchi,M., Adachi,H., Kawai,H., Urabe,T., Yanagi,M., Matsui,O., and . (1993). High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 40, 305-310. NLM: 94010666

  8. Shiratori,Y., Shiina,S., Imamura,M., Kato,N., Kanai,F., Okudaira,T., Teratani,T., Tohgo,G., Toda,N., Ohashi,M., and . (1995). Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 22, 1027-1033. NLM: 96029406

  9. Lanier,A.P., McMahon,B.J., Alberts,S.R., Popper,H., and Heyward,W.L. (1987). Primary liver cancer in Alaskan natives. 1980-1985. Cancer 60, 1915-1920. NLM: 88001951

  10. Kiyosawa,K., Sodeyama,T., Tanaka,E., Gibo,Y., Yoshizawa,K., Nakano,Y., Furuta,S., Akahane,Y., Nishioka,K., Purcell,R.H., and . (1990). Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12, 671-675. NLM: 91007680

  11. Ishak,K.G. (1994). Chronic hepatitis: morphology and nomenclature. Mod. Pathol. 7, 690-713. NLM: 95083579

  12. Simpson,K.J., Lukacs,N.W., Colletti,L., Strieter,R.M., and Kunkel,S.L. (1997). Cytokines and the liver. J. Hepatol. 27, 1120-1132. NLM: 98114187

  13. Kagi,D., Ledermann,B., Burki,K., Zinkernagel,R.M., and Hengartner,H. (1996). Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 14:207-32., 207-232. NLM: 96292427

  14. Steinhoff,G., Behrend,M., Schrader,B., Duijvestijn,A.M., and Wonigeit,K. (1993). Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia. Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2, and LFA- 3. Am. J. Pathol. 142, 481-488. NLM: 93167351

  15. McNab,G., Reeves,J.L., Salmi,M., Hubscher,S., Jalkanen,S., and Adams,D.H. (1996). Vascular adhesion protein 1 mediates binding of T cells to human hepatic endothelium. Gastroenterology 110, 522-528. NLM: 96156055

  16. Salmi,M., Adams,D., and Jalkanen,S. (1998). Cell adhesion and migration. IV. Lymphocyte trafficking in the intestine and liver. Am. J. Physiol 274, G1-G6. NLM: 98120387

  17. Yoong,K.F., McNab,G., Hubscher,S.G., and Adams,D.H. (1998). Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor- infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160, 3978-3988. NLM: 98217189

  18. Shimoda,R., Nagashima,M., Sakamoto,M., Yamaguchi,N., Hirohashi,S., Yokota,J., and Kasai,H. (1994). Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res. 54, 3171-3172. NLM: 94265162

  19. Anthony,P.P., Ishak,K.G., Nayak,N.C., Poulsen,H.E., Scheuer,P.J., and Sobin,L.H. (1978). The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J. Clin. Pathol. 31, 395-414. NLM: 78171817

  20. La Vecchia,C., Negri,E., Cavalieri,d.L., and Franceschi,S. (1998). Liver cirrhosis and the risk of primary liver cancer. Eur. J. Cancer Prev. 7, 315-320. NLM: 99023067

  21. Bannasch,P. and Klinge,O. (1971). [Hepatocellular glycogenosis and hepatoma development in man]. Virchows Arch. A Pathol. Pathol. Anat. 352, 157-164. NLM: 71115962

  22. Cain,H. and Kraus,B. (1977). [Developmental anomalies of the liver and carcinoma of the liver in infants and children (author's transl)]. Dtsch. Med. Wochenschr. 102, 505-509. NLM: 77161747

  23. Uchida,T., Miyata,H., and Shikata,T. (1981). Human hepatocellular carcinoma and putative precancerous disorders: their enzyme histochemical study. Arch. Pathol. Lab Med. 105, 180-186. NLM: 81159367

  24. Hirota,N., Hamazaki,M., and Williams,G.M. (1982). Resistance to iron accumulation and presence of hepatitis B surface antigen in preneoplastic and neoplastic lesions in human hemochromatotic livers. Hepatogastroenterology 29, 49-51. NLM: 82212226

  25. Terada,T. and Nakanuma,Y. (1989). Survey of iron-accumulative macroregenerative nodules in cirrhotic livers. Hepatology 10, 851-854. NLM: 90034691

  26. Govindarajan,S., Conrad,A., Lim,B., Valinluck,B., Kim,A.M., and Schmid,P. (1990). Study of preneoplastic changes of liver cells by immunohistochemical and molecular hybridization techniques. Arch. Pathol. Lab Med. 114, 1042-1045. NLM: 91024517

  27. Terada,T., Kadoya,M., Nakanuma,Y., and Matsui,O. (1990). Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 65, 1994-2000. NLM: 90322313

  28. Deugnier,Y.M., Charalambous,P., Le Quilleuc,D., Turlin,B., Searle,J., Brissot,P., Powell,L.W., and Halliday,J.W. (1993). Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology 18, 1363-1369. NLM: 94063771

  29. Karhunen,P.J. and Penttila,A. (1987). Preneoplastic lesions of human liver. Hepatogastroenterology 34, 10-15. NLM: 87192399

  30. Bannasch,P., Jahn,U.R., Hacker,H.J., Su,Q., Hofmann,W., Pichlmayr,R., and Otto,G. (1997). Focal hepatic glycogenosis: a putative preneoplastic lesion associated with neoplasia and cirrhosis in explanted human livers. Int. J. Oncol. 10:261-268, 261-268.

  31. Su,Q., Benner,A., Hofmann,W.J., Otto,G., Pichlmayr,R., and Bannasch,P. (1997). Human hepatic preneoplasia: phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their relationship to liver cell dysplasia. Virchows Arch. 431, 391-406. NLM: 98090606

  32. Sugitani,S., Sakamoto,M., Ichida,T., Genda,T., Asakura,H., and Hirohashi,S. (1998). Hyperplastic foci reflect the risk of multicentric development of human hepatocellular carcinoma. J. Hepatol. 28, 1045-1053. NLM: 98335903

  33. Terasaki,S., Kaneko,S., Kobayashi,K., Nonomura,A., and Nakanuma,Y. (1998). Histological features predicting malignant transformation of nonmalignant hepatocellular nodules: a prospective study. Gastroenterology 115, 1216-1222. NLM: 99014209

  34. Theise,N.D. (1995). Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin. Liver Dis. 15, 360-371. NLM: 96157984

  35. (1995). Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 22, 983-993. NLM: 95386144

  36. Popper,H., Thung,S.N., McMahon,B.J., Lanier,A.P., Hawkins,I., and Alberts,S.R. (1988). Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. Arch. Pathol. Lab Med. 112, 498-504. NLM: 88192320

  37. Theise,N.D., Lapook,J.D., and Thung,S.N. (1993). A macroregenerative nodule containing multiple foci of hepatocellular carcinoma in a noncirrhotic liver. Hepatology 17, 993-996. NLM: 93293165

  38. Sakamoto,M., Hirohashi,S., and Shimosato,Y. (1991). Early stages of multistep hepatocarcinogenesis: adenomatous hyperplasia and early hepatocellular carcinoma. Hum. Pathol. 22, 172-178. NLM: 91161150

  39. Edmundson,H.A. and Steiner,P.E. (1954). Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 7:462-503, 462-503.

  40. Ebara,M., Ohto,M., Shinagawa,T., Sugiura,N., Kimura,K., Matsutani,S., Morita,M., Saisho,H., Tsuchiya,Y., and Okuda,K. (1986). Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology 90, 289-298. NLM: 86083011

  41. Yoshino,M. (1983). Growth kinetics of hepatocellular carcinoma. Jpn. J. Clin. Oncol. 13, 45-52. NLM: 83164826

  42. Sheu,J.C., Sung,J.L., Chen,D.S., Yang,P.M., Lai,M.Y., Lee,C.S., Hsu,H.C., Chuang,C.N., Yang,P.C., Wang,T.H., and . (1985). Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 89, 259-266. NLM: 85231877

  43. Okada,S., Okazaki,N., Nose,H., Aoki,K., Kawano,N., Yamamoto,J., Shimada,K., Takayama,T., Kosuge,T., and Yamasaki,S. (1993). Follow-up examination schedule of postoperative HCC patients based on tumor volume doubling time. Hepatogastroenterology 40, 311-315. NLM: 94010667

  44. Barbara,L., Benzi,G., Gaiani,S., Fusconi,F., Zironi,G., Siringo,S., Rigamonti,A., Barbara,C., Grigioni,W., Mazziotti,A., and . (1992). Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 16, 132-137. NLM: 92316462

  45. Tarao,K., Shimizu,A., Harada,M., Kuni,Y., Ito,Y., Tamai,S., Iimori,K., Sugimasa,Y., Takemiya,S., Okamoto,T., and . (1989). Difference in the in vitro uptake of bromodeoxyuridine between liver cirrhosis with and without hepatocellular carcinoma. Cancer 64, 104-109. NLM: 89274970

  46. Tarao,K., Ohkawa,S., Shimizu,A., Harada,M., Nakamura,Y., Okamoto,N., Ito,Y., Tamai,S., Iimori,K., Sugimasa,Y., and . (1993). DNA synthesis activities of hepatocytes from noncancerous cirrhotic tissue and of hepatocellular carcinoma (HCC) cells from cancerous tissue can predict the survival of hepatectomized patients with HCC. Cancer 71, 3859-3863. NLM: 93284496

  47. Tarao,K., Shimizu,A., Harada,M., Ohkawa,S., Okamoto,N., Kuni,Y., Ito,Y., Tamai,S., Iimori,K., Sugimasa,I., and . (1991). In vitro uptake of bromodeoxyuridine by human hepatocellular carcinoma and its relation to histopathologic findings and biologic behavior. Cancer 68, 1789-1794. NLM: 92005267

  48. Hino,N., Higashi,T., Nouso,K., Nakatsukasa,H., and Tsuji,T. (1996). Apoptosis and proliferation of human hepatocellular carcinoma. Liver 16, 123-129. NLM: 96303371

  49. Grasl-Kraupp,B., Ruttkay-Nedecky,B., Mullauer,L., Taper,H., Huber,W., Bursch,W., and Schulte-Hermann,R. (1997). Inherent increase of apoptosis in liver tumors: implications for carcinogenesis and tumor regression. Hepatology 25, 906-912. NLM: 97250913

  50. Kubo,K., Matsuzaki,Y., Okazaki,M., Kato,A., Kobayashi,N., and Okita,K. (1998). The Fas system is not significantly involved in apoptosis in human hepatocellular carcinoma. Liver 18, 117-123. NLM: 98248184

  51. Tannapfel,A., Geissler,F., Kockerling,F., Katalinic,A., Hauss,J., and Wittekind,C. (1999). Apoptosis and proliferation in relation to histopathological variables and prognosis in hepatocellular carcinoma. J. Pathol. 187, 439-445. NLM: 99359534

  52. Tiniakos,D.G. and Brunt,E.M. (1999). Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 19, 58-68. NLM: 99125848

  53. Matsuno,Y., Hirohashi,S., Furuya,S., Sakamoto,M., Mukai,K., and Shimosato,Y. (1990). Heterogeneity of proliferative activity in nodule-in-nodule lesions of small hepatocellular carcinoma. Jpn. J. Cancer Res. 81, 1137-1140. NLM: 91092974

  54. Le Bail,B., Belleannee,G., Bernard,P.H., Saric,J., Balabaud,C., and Bioulac-Sage,P. (1995). Adenomatous hyperplasia in cirrhotic livers: histological evaluation, cellular density, and proliferative activity of 35 macronodular lesions in the cirrhotic explants of 10 adult French patients. Hum. Pathol. 26, 897-906. NLM: 95362230

  55. Borzio,M., Trere,D., Borzio,F., Ferrari,A.R., Bruno,S., Roncalli,M., Colloredo,G., Leandro,G., Oliveri,F., and Derenzini,M. (1998). Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol. Pathol. 51, 96-101. NLM: 98379215

  56. Tarao,K., Ohkawa,S., Shimizu,A., Harada,M., Nakamura,Y., Ito,Y., Tamai,S., Hoshino,H., Inoue,T., and Kanisawa,M. (1994). Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer 73, 1149-1154. NLM: 94147333

  57. Ng,I.O., Lai,E.C., Fan,S.T., Ng,M., Chan,A.S., and So,M.K. (1994). Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 73, 2268-2274. NLM: 94221521

  58. Dutta,U., Kench,J., Byth,K., Khan,M.H., Lin,R., Liddle,C., and Farrell,G.C. (1998). Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum. Pathol. 29, 1279-1284. NLM: 99039713

  59. Wu,P.C., Lau,V.K., Fang,J.W., Lai,V.C., Lai,C.L., and Lau,J.Y. (1999). Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. Liver 19, 444-451. NLM: 20001372

  60. Ito,Y., Matsuura,N., Sakon,M., Takeda,T., Umeshita,K., Nagano,H., Nakamori,S., Dono,K., Tsujimoto,M., Nakahara,M., Nakao,K., and Monden,M. (1999). Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br. J. Cancer 81, 747-751. NLM: 20039423

  61. Shafritz,D.A., Shouval,D., Sherman,H.I., Hadziyannis,S.J., and Kew,M.C. (1981). Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med. 305, 1067-1073. NLM: 82013535

  62. Esumi,M., Aritaka,T., Arii,M., Suzuki,K., Tanikawa,K., Mizuo,H., Mima,T., and Shikata,T. (1986). Clonal origin of human hepatoma determined by integration of hepatitis B virus DNA. Cancer Res. 46, 5767-5771. NLM: 87002199

  63. Govindarajan,S., Craig,J.R., and Valinluck,B. (1988). Clonal origin of hepatitis B virus-associated hepatocellular carcinoma. Hum. Pathol. 19, 403-405. NLM: 88212390

  64. Tsuda,H., Hirohashi,S., Shimosato,Y., Terada,M., and Hasegawa,H. (1988). Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 95, 1664-1666. NLM: 89031828

  65. Aoki,N. and Robinson,W.S. (1989). State of hepatitis B viral genomes in cirrhotic and hepatocellular carcinoma nodules. Mol. Biol. Med. 6, 395-408. NLM: 90173781

  66. Chen,P.J., Chen,D.S., Lai,M.Y., Chang,M.H., Huang,G.T., Yang,P.M., Sheu,J.C., Lee,S.C., Hsu,H.C., and Sung,J.L. (1989). Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology 96, 527-529. NLM: 89091949

  67. Sakamoto,M., Hirohashi,S., Tsuda,H., Shimosato,Y., Makuuchi,M., and Hosoda,Y. (1989). Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am. J. Surg. Pathol. 13, 1064-1067. NLM: 90087180

  68. Hsu,H.C., Chiou,T.J., Chen,J.Y., Lee,C.S., Lee,P.H., and Peng,S.Y. (1991). Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 13, 923-928. NLM: 91231259

  69. Sheu,J.C., Huang,G.T., Chou,H.C., Lee,P.H., Wang,J.T., Lee,H.S., and Chen,D.S. (1993). Multiple hepatocellular carcinomas at the early stage have different clonality. Gastroenterology 105, 1471-1476. NLM: 94040502

  70. Aihara,T., Noguchi,S., Sasaki,Y., Nakano,H., and Imaoka,S. (1994). Clonal analysis of regenerative nodules in hepatitis C virus-induced liver cirrhosis. Gastroenterology 107, 1805-1811. NLM: 95047161

  71. Kawai,S., Imazeki,F., Yokosuka,O., Ohto,M., Shiina,S., Kato,N., and Omata,M. (1995). Clonality in hepatocellular carcinoma: analysis of methylation pattern of polymorphic X-chromosome-linked phosphoglycerate kinase gene in females. Hepatology 22, 112-117. NLM: 95324861

  72. Aihara,T., Noguchi,S., Sasaki,Y., Nakano,H., Monden,M., and Imaoka,S. (1996). Clonal analysis of precancerous lesion of hepatocellular carcinoma. Gastroenterology 111, 455-461. NLM: 96305115

  73. Paradis,V., Laurent,A., Flejou,J.F., Vidaud,M., and Bedossa,P. (1997). Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 26, 891-895. NLM: 97466970

  74. Yamamoto,T., Kajino,K., Kudo,M., Sasaki,Y., Arakawa,Y., and Hino,O. (1999). Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology 29, 1446-1452. NLM: 99234125

  75. Sirivatanauksorn,Y., Sirivatanauksorn,V., Bhattacharya,S., Davidson,B.R., Dhillon,A.P., Kakkar,A.K., Williamson,R.C., and Lemoine,N.R. (1999). Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting. J. Pathol. 189, 344-350. NLM: 20016449

  76. Kam,W., Rall,L.B., Smuckler,E.A., Schmid,R., and Rutter,W.J. (1982). Hepatitis B viral DNA in liver and serum of asymptomatic carriers. Proc. Natl. Acad. Sci. U. S. A 79, 7522-7526. NLM: 83117711

  77. Hada,H., Arima,T., Togawa,K., Okada,Y., Morichika,S., and Nagashima,H. (1986). State of hepatitis B viral DNA in the liver of patients with hepatocellular carcinoma and chronic liver disease. Liver 6, 189-198. NLM: 87038625

  78. Tanaka,Y., Esumi,M., and Shikata,T. (1988). Frequent integration of hepatitis B virus DNA in noncancerous liver tissue from hepatocellular carcinoma patients. J. Med. Virol. 26, 7-14. NLM: 89036182

  79. Yasui,H., Hino,O., Ohtake,K., Machinami,R., and Kitagawa,T. (1992). Clonal growth of hepatitis B virus-integrated hepatocytes in cirrhotic liver nodules. Cancer Res. 52, 6810-6814. NLM: 93092124

  80. Grigioni,W.F., Garbisa,S., D'Errico,A., Baccarini,P., Stetler-Stevenson,W.G., Liotta,L.A., and Mancini,A.M. (1991). Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am. J. Pathol. 138, 647-654. NLM: 91157971

  81. Yamada,S., Ichida,T., Matsuda,Y., Miyazaki,Y., Hatano,T., Hata,K., Asakura,H., Hirota,N., Geerts,A., and Wisse,E. (1992). Tenascin expression in human chronic liver disease and in hepatocellular carcinoma. Liver 12, 10-16. NLM: 92227653

  82. Scoazec,J.Y., Flejou,J.F., D'Errico,A., Fiorentino,M., Zamparelli,A., Bringuier,A.F., Feldmann,G., and Grigioni,W.F. (1996). Fibrolamellar carcinoma of the liver: composition of the extracellular matrix and expression of cell-matrix and cell-cell adhesion molecules. Hepatology 24, 1128-1136. NLM: 97060352

  83. Hayashi,K., Kurohiji,T., and Shirouzu,K. (1997). Localization of thrombospondin in hepatocellular carcinoma. Hepatology 25, 569-574. NLM: 97201414

  84. Le Bail,B., Faouzi,S., Boussarie,L., Balabaud,C., Bioulac-Sage,P., and Rosenbaum,J. (1997). Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J. Pathol. 181, 330-337. NLM: 97300701

  85. Roskams,T., De Vos,R., David,G., Van Damme,B., and Desmet,V. (1998). Heparan sulphate proteoglycan expression in human primary liver tumours. J. Pathol. 185, 290-297. NLM: 98444445

  86. Grigioni,W.F., D'Errico,A., Mancini,A.M., Biagini,G., Gozzetti,G., Mazziotti,A., and Garbisa,S. (1987). Hepatocellular carcinoma: expression of basement membrane glycoproteins. An immunohistochemical approach. J. Pathol. 152, 325-332. NLM: 88035417

  87. Donato,M.F., Colombo,M., Matarazzo,M., and Paronetto,F. (1989). Distribution of basement membrane components in human hepatocellular carcinoma. Cancer 63, 272-279. NLM: 89089527

  88. Jaskiewicz,K., Chasen,M.R., and Robson,S.C. (1993). Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res. 13, 2229-2237. NLM: 94127849

  89. Yao,M., Zhou,D.P., Jiang,S.M., Wang,Q.H., Zhou,X.D., Tang,Z.Y., and Gu,J.X. (1998). Elevated activity of N-acetylglucosaminyltransferase V in human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 124, 27-30. NLM: 98158596

  90. Volpes,R., van den Oord,J.J., and Desmet,V.J. (1991). Distribution of the VLA family of integrins in normal and pathological human liver tissue. Gastroenterology 101, 200-206. NLM: 91257512

  91. Patriarca,C., Roncalli,M., Gambacorta,M., Cominotti,M., Coggi,G., and Viale,G. (1993). Patterns of integrin common chain beta 1 and collagen IV immunoreactivity in hepatocellular carcinoma. Correlations with tumour growth rate, grade and size. J. Pathol. 171, 5-11. NLM: 94046189

  92. Volpes,R., van den Oord,J.J., and Desmet,V.J. (1993). Integrins as differential cell lineage markers of primary liver tumors. Am. J. Pathol. 142, 1483-1492. NLM: 93263215

  93. Couvelard,A., Bringuier,A.F., Dauge,M.C., Nejjari,M., Darai,E., Benifla,J.L., Feldmann,G., Henin,D., and Scoazec,J.Y. (1998). Expression of integrins during liver organogenesis in humans. Hepatology 27, 839-847. NLM: 98160351

  94. Ozaki,I., Yamamoto,K., Mizuta,T., Kajihara,S., Fukushima,N., Setoguchi,Y., Morito,F., and Sakai,T. (1998). Differential expression of laminin receptors in human hepatocellular carcinoma. Gut 43, 837-842. NLM: 99071287

  95. Begum,N.A., Mori,M., Matsumata,T., Takenaka,K., Sugimachi,K., and Barnard,G.F. (1995). Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 22, 1447-1455. NLM: 96054964

  96. Shimoyama,Y. and Hirohashi,S. (1991). Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett. 57, 131-135. NLM: 91223517

  97. Haramaki,M., Yano,H., Fukuda,K., Momosaki,S., Ogasawara,S., and Kojiro,M. (1995). Expression of CD44 in human hepatocellular carcinoma cell lines. Hepatology 21, 1276-1284. NLM: 95255796

  98. Huang,L.R. and Hsu,H.C. (1995). Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res. 55, 4717-4721. NLM: 96006225

  99. Ihara,A., Koizumi,H., Hashizume,R., and Uchikoshi,T. (1996). Expression of epithelial cadherin and alpha- and beta-catenins in nontumoral livers and hepatocellular carcinomas. Hepatology 23, 1441-1447. NLM: 96243164

  100. Kozyraki,R., Scoazec,J.Y., Flejou,J.F., D'Errico,A., Bedossa,P., Terris,B., Fiorentino,M., Bringuier,A.F., Grigioni,W.F., and Feldmann,G. (1996). Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 110, 1137-1149. NLM: 96183151

  101. Mathew,J., Hines,J.E., Obafunwa,J.O., Burr,A.W., Toole,K., and Burt,A.D. (1996). CD44 is expressed in hepatocellular carcinomas showing vascular invasion. J. Pathol. 179, 74-79. NLM: 96296845

  102. Terris,B., Laurent-Puig,P., Belghitti,J., Degott,C., Henin,D., and Flejou,J.F. (1997). Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. Int. J. Cancer 74, 614-619. NLM: 98081711

  103. Kanai,Y., Ushijima,S., Hui,A.M., Ochiai,A., Tsuda,H., Sakamoto,M., and Hirohashi,S. (1997). The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int. J. Cancer 71, 355-359. NLM: 97284453

  104. de Boer,C.J., van Krieken,J.H., Janssen-van Rhijn,C.M., and Litvinov,S.V. (1999). Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J. Pathol. 188, 201-206. NLM: 99359596

  105. Yamaoka,K., Nouchi,T., Tazawa,J., Hiranuma,S., Marumo,F., and Sato,C. (1995). Expression of gap junction protein connexin 32 and E-cadherin in human hepatocellular carcinoma. J. Hepatol. 22, 536-539. NLM: 95378616

  106. Slagle,B.L., Zhou,Y.Z., Birchmeier,W., and Scorsone,K.A. (1993). Deletion of the E-cadherin gene in hepatitis B virus-positive Chinese hepatocellular carcinomas. Hepatology 18, 757-762. NLM: 94010737

  107. Falleti,E., Fabris,C., Pirisi,M., Soardo,G., Vitulli,D., Toniutto,P., Bartoli,E., Bortolotti,N., and Gonano,F. (1996). Circulating intercellular adhesion molecule 1 predicts non-specific elevation of alpha 1-fetoprotein. J. Cancer Res. Clin. Oncol. 122, 366-369. NLM: 96236421

  108. Okazaki,I., Wada,N., Nakano,M., Saito,A., Takasaki,K., Doi,M., Kameyama,K., Otani,Y., Kubochi,K., Niioka,M., Watanabe,T., and Maruyama,K. (1997). Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 25, 580-584. NLM: 97201416

  109. Arii,S., Mise,M., Harada,T., Furutani,M., Ishigami,S., Niwano,M., Mizumoto,M., Fukumoto,M., and Imamura,M. (1996). Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24, 316-322. NLM: 96319473

  110. Hayasaka,A., Suzuki,N., Fujimoto,N., Iwama,S., Fukuyama,E., Kanda,Y., and Saisho,H. (1996). Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma. Hepatology 24, 1058-1062. NLM: 97060340

  111. Nakatsukasa,H., Ashida,K., Higashi,T., Ohguchi,S., Tsuboi,S., Hino,N., Nouso,K., Urabe,Y., Kinugasa,N., Yoshida,K., Uematsu,S., Ishizaki,M., Kobayashi,Y., and Tsuji,T. (1996). Cellular distribution of transcripts for tissue inhibitor of metalloproteinases 1 and 2 in human hepatocellular carcinomas. Hepatology 24, 82-88. NLM: 96317610

  112. De Petro,G., Tavian,D., Copeta,A., Portolani,N., Giulini,S.M., and Barlati,S. (1998). Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 58, 2234-2239. NLM: 98266808

  113. Morita,Y., Hayashi,Y., Wang,Y., Kanamaru,T., Suzuki,S., Kawasaki,K., Ohta,K., Yamamoto,M., Saitoh,Y., Itoh,H., and Doe,W.F. (1997). Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 25, 856-861. NLM: 97250905

  114. Akahane,T., Ishii,M., Ohtani,H., Nagura,H., and Toyota,T. (1998). Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 18, 414-419. NLM: 99084741

  115. Dubuisson,L., Monvoisin,A., Nielsen,B.S., Le Bail,B., Bioulac-Sage,P., and Rosenbaum,J. (2000). Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J. Pathol. 190, 190-195. NLM: 20124027

  116. Huber,K., Kirchheimer,J.C., Ermler,D., Bell,C., and Binder,B.R. (1992). Determination of plasma urokinase-type plasminogen activator antigen in patients with primary liver cancer: characterization as tumor- associated antigen and comparison with alpha-fetoprotein. Cancer Res. 52, 1717-1720. NLM: 92200375

  117. Hanss,M., Bonvoisin,C., Patouillard,T., Martin,D., Audigier,J.C., Descos,L., and Dechavanne,M. (1994). Increased plasma levels of urokinase-type plasminogen activator during hepatocellular carcinoma. Fibrinolysis 8:255-270, 255-270.

  118. Booth,N.A., Anderson,J.A., and Bennett,B. (1984). Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator. J. Clin. Pathol. 37, 772-777. NLM: 84265341

  119. Sato,S., Higashi,T., Ouguchi,S., Hino,N., and Tsuji,T. (1994). Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma. J. Gastroenterol. 29, 745-750. NLM: 95179281

  120. Toyoda,H., Fukuda,Y., Hayakawa,T., Kumada,T., and Nakano,S. (1997). Changes in blood supply in small hepatocellular carcinoma: correlation of angiographic images and immunohistochemical findings. J. Hepatol. 27, 654-660. NLM: 98030323

  121. Haratake,J. and Scheuer,P.J. (1990). An immunohistochemical and ultrastructural study of the sinusoids of hepatocellular carcinoma. Cancer 65, 1985-1993. NLM: 90322312

  122. Haratake,J., Hisaoka,M., Yamamoto,O., and Horie,A. (1992). An ultrastructural comparison of sinusoids in hepatocellular carcinoma, adenomatous hyperplasia, and fetal liver. Arch. Pathol. Lab Med. 116, 67-70. NLM: 92134145

  123. Terada,T. and Nakanuma,Y. (1991). Expression of ABH blood group antigens, Ulex europaeus agglutinin I, and type IV collagen in the sinusoids of hepatocellular carcinoma. Arch. Pathol. Lab Med. 115, 50-55. NLM: 91103669

  124. Dhillon,A.P., Colombari,R., Savage,K., and Scheuer,P.J. (1992). An immunohistochemical study of the blood vessels within primary hepatocellular tumours. Liver 12, 311-318. NLM: 93078601

  125. Ueda,K., Terada,T., Nakanuma,Y., and Matsui,O. (1992). Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: a morphometric study. Hum. Pathol. 23, 619-626. NLM: 92275590

  126. Ruck,P., Xiao,J.C., and Kaiserling,E. (1995). Immunoreactivity of sinusoids in hepatocellular carcinoma. An immunohistochemical study using lectin UEA-1 and antibodies against endothelial markers, including CD34. Arch. Pathol. Lab Med. 119, 173-178. NLM: 95150792

  127. Tanigawa,N., Lu,C., Mitsui,T., and Miura,S. (1997). Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 26, 1216-1223. NLM: 98026688

  128. Kimura,H., Nakajima,T., Kagawa,K., Deguchi,T., Kakusui,M., Katagishi,T., Okanoue,T., Kashima,K., and Ashihara,T. (1998). Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 18, 14-19. NLM: 98208039

  129. El Assal,O.N., Yamanoi,A., Soda,Y., Yamaguchi,M., Igarashi,M., Yamamoto,A., Nabika,T., and Nagasue,N. (1998). Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27, 1554-1562. NLM: 98281636

  130. Park,Y.N., Yang,C.P., Fernandez,G.J., Cubukcu,O., Thung,S.N., and Theise,N.D. (1998). Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am. J. Surg. Pathol. 22, 656-662. NLM: 98292124

  131. Scott,F.R., el Refaie,A., More,L., Scheuer,P.J., and Dhillon,A.P. (1996). Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma. Histopathology 28, 472-474. NLM: 96330758

  132. Kar,S., Yousem,S.A., and Carr,B.I. (1995). Endothelin-1 expression by human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 216, 514-519. NLM: 96063638

  133. Fischer,G., Hartmann,H., Droese,M., Schauer,A., and Bock,K.W. (1986). Histochemical and immunohistochemical detection of putative preneoplastic liver foci in women after long-term use of oral contraceptives. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 50, 321-337. NLM: 86181560

  134. Grigioni,W.F., D'Errico,A., Bacci,F., Gaudio,M., Mazziotti,A., Gozzetti,G., and Mancini,A.M. (1989). Primary liver neoplasms: evaluation of proliferative index using MoAb Ki67. J. Pathol. 158, 23-29. NLM: 89328656

  135. Gaffey,M.J., Iezzoni,J.C., and Weiss,L.M. (1996). Clonal analysis of focal nodular hyperplasia of the liver. Am. J. Pathol. 148, 1089-1096. NLM: 96247687

  136. Castilla,A., Prieto,J., and Fausto,N. (1991). Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med. 324, 933-940. NLM: 91163595

  137. Hsia,C.C., Axiotis,C.A., Di Bisceglie,A.M., and Tabor,E. (1992). Transforming growth factor-alpha in human hepatocellular carcinoma and coexpression with hepatitis B surface antigen in adjacent liver. Cancer 70, 1049-1056. NLM: 92386382

  138. Collier,J.D., Guo,K., Gullick,W.J., Bassendine,M.F., and Burt,A.D. (1993). Expression of transforming growth factor alpha in human hepatocellular carcinoma. Liver 13, 151-155. NLM: 93330000

  139. Schaff,Z., Hsia,C.C., Sarosi,I., and Tabor,E. (1994). Overexpression of transforming growth factor-alpha in hepatocellular carcinoma and focal nodular hyperplasia from European patients. Hum. Pathol. 25, 644-651. NLM: 94299241

  140. Morimitsu,Y., Hsia,C.C., Kojiro,M., and Tabor,E. (1995). Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum. Pathol. 26, 1126-1132. NLM: 96013933

  141. Nalesnik,M.A., Lee,R.G., and Carr,B.I. (1998). Transforming growth factor alpha (TGFalpha) in hepatocellular carcinomas and adjacent hepatic parenchyma. Hum. Pathol. 29, 228-234. NLM: 98156538

  142. Hsia,C.C., Thorgeirsson,S.S., and Tabor,E. (1994). Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in "oval cells" of the liver in patients with hepatocellular carcinoma. J. Med. Virol. 43, 216-221. NLM: 95016548

  143. Masuhara,M., Yasunaga,M., Tanigawa,K., Tamura,F., Yamashita,S., Sakaida,I., and Okita,K. (1996). Expression of hepatocyte growth factor, transforming growth factor alpha, and transforming growth factor beta 1 messenger RNA in various human liver diseases and correlation with hepatocyte proliferation. Hepatology 24, 323-329. NLM: 96319474

  144. Harada,K., Shiota,G., and Kawasaki,H. (1999). Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 19, 318-325. NLM: 99387387

  145. Yamaguchi,M., Yu,L., Hishikawa,Y., Yamanoi,A., Kubota,H., and Nagasue,N. (1997). Growth kinetic study of human hepatocellular carcinoma using proliferating cell nuclear antigen and Lewis Y antigen: their correlation with transforming growth factor-alpha and beta 1. Oncology 54, 245-251. NLM: 97288429

  146. Park,B.C., Huh,M.H., and Seo,J.H. (1995). Differential expression of transforming growth factor alpha and insulin- like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J. Hepatol. 22, 286-294. NLM: 95332652

  147. Tanaka,S., Takenaka,K., Matsumata,T., Mori,R., and Sugimachi,K. (1996). Hepatitis C virus replication is associated with expression of transforming growth factor-alpha and insulin-like growth factor-II in cirrhotic livers. Dig. Dis. Sci. 41, 208-215. NLM: 96160759

  148. Ono,M., Morisawa,K., Nie,J., Ota,K., Taniguchi,T., Saibara,T., and Onishi,S. (1998). Transactivation of transforming growth factor alpha gene by hepatitis B virus preS1. Cancer Res. 58, 1813-1816. NLM: 98240974

  149. Morimitsu,Y., Kleiner,D.E., Jr., Conjeevaram,H.S., Hsia,C.C., Di Bisceglie,A.M., and Tabor,E. (1995). Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Hepatology 22, 1021-1026. NLM: 96029405

  150. Yamaguchi,K., Carr,B.I., and Nalesnik,M.A. (1995). Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J. Surg. Oncol. 58, 240-245. NLM: 95240103

  151. Kiss,A., Wang,N.J., Xie,J.P., and Thorgeirsson,S.S. (1997). Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin. Cancer Res. 3, 1059-1066. NLM: 99111033

  152. Tang,Z., Qin,L., Wang,X., Zhou,G., Liao,Y., Weng,Y., Jiang,X., Lin,Z., Liu,K., and Ye,S. (1998). Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med. J. (Engl. ) 111, 313-318. NLM: 99302624

  153. Tomiya,T. and Fujiwara,K. (1996). Serum transforming growth factor alpha level as a marker of hepatocellular carcinoma complicating cirrhosis. Cancer 77, 1056-1060. NLM: 96232455

  154. Yeh,Y.C., Tsai,J.F., Chuang,L.Y., Yeh,H.W., Tsai,J.H., Florine,D.L., and Tam,J.P. (1987). Elevation of transforming growth factor alpha and its relationship to the epidermal growth factor and alpha-fetoprotein levels in patients with hepatocellular carcinoma. Cancer Res. 47, 896-901. NLM: 87102632

  155. Motoo,Y., Sawabu,N., and Nakanuma,Y. (1991). Expression of epidermal growth factor and fibroblast growth factor in human hepatocellular carcinoma: an immunohistochemical study. Liver 11, 272-277. NLM: 92072420

  156. Chuang,L.Y., Tsai,J.H., Yeh,Y.C., Chang,C.C., Yeh,H.W., Guh,J.Y., and Tsai,J.F. (1991). Epidermal growth factor-related transforming growth factors in the urine of patients with hepatocellular carcinoma. Hepatology 13, 1112-1116. NLM: 91267469

  157. Hamazaki,K., Yunoki,Y., Tagashira,H., Mimura,T., Mori,M., and Orita,K. (1997). Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect. Prev. 21, 355-360. NLM: 97376155

  158. Kaneko,Y., Shibuya,M., Nakayama,T., Hayashida,N., Toda,G., Endo,Y., Oka,H., and Oda,T. (1985). Hypomethylation of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn. J. Cancer Res. 76, 1136-1140. NLM: 86139491

  159. Mori,S., Akiyama,T., Morishita,Y., Shimizu,S., Sakai,K., Sudoh,K., Toyoshima,K., and Yamamoto,T. (1987). Light and electron microscopical demonstration of c- erB-2 gene product- like immunoreactivity in human malignant tumors. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 54, 8-15. NLM: 88101348

  160. Brunt,E.M. and Swanson,P.E. (1992). Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver. Am. J. Clin. Pathol. 97, S53-S61. NLM: 92246171

  161. Collier,J.D., Guo,K., Mathew,J., May,F.E., Bennett,M.K., Corbett,I.P., Bassendine,M.F., and Burt,A.D. (1992). c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J. Hepatol. 14, 377-380. NLM: 92364286

  162. Heinze,T., Jonas,S., Karsten,A., and Neuhaus,P. (1999). Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. Anticancer Res. 19, 2501-2503. NLM: 99399168

  163. Luo,J.C., Yu,M.W., Chen,C.J., Santella,R.M., Carney,W.P., and Brandt-Rauf,P.W. (1993). Serum c-erbB-2 oncopeptide in hepatocellular carcinogenesis. Med. Sci. Res. 21:305-307, 305-307.

  164. Cariani,E., Seurin,D., Lasserre,C., Franco,D., Binoux,M., and Brechot,C. (1990). Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis. J. Hepatol. 11, 226-231. NLM: 91072931

  165. Su,Q., Liu,Y.F., Zhang,J.F., Zhang,S.X., Li,D.F., and Yang,J.J. (1994). Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 20, 788-799. NLM: 95012092

  166. Fiorentino,M., Grigioni,W.F., Baccarini,P., D'Errico,A., De Mitri,M.S., Pisi,E., and Mancini,A.M. (1994). Different in situ expression of insulin-like growth factor type II in hepatocellular carcinoma. An in situ hybridization and immunohistochemical study. Diagn. Mol. Pathol. 3, 59-65. NLM: 94214769

  167. Sohda,T., Yun,K., Iwata,K., Soejima,H., and Okumura,M. (1996). Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 75, 307-311. NLM: 96397460

  168. Sohda,T., Kamimura,S., Iwata,K., Shijo,H., and Okumura,M. (1997). Immunohistochemical evidence of insulin-like growth factor II in human small hepatocellular carcinoma with hepatitis C virus infection: relationship to fatty change in carcinoma cells. J. Gastroenterol. Hepatol. 12, 224-228. NLM: 97287547

  169. Cariani,E., Lasserre,C., Seurin,D., Hamelin,B., Kemeny,F., Franco,D., Czech,M.P., Ullrich,A., and Brechot,C. (1988). Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 48, 6844-6849. NLM: 89028358

  170. Cariani,E., Lasserre,C., Kemeny,F., Franco,D., and Brechot,C. (1991). Expression of insulin-like growth factor II, alpha-fetoprotein and hepatitis B virus transcripts in human primary liver cancer. Hepatology 13, 644-649. NLM: 91184715

  171. Su,T.S., Liu,W.Y., Han,S.H., Jansen,M., Yang-Fen,T.L., P'eng,F.K., and Chou,C.K. (1989). Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res. 49, 1773-1777. NLM: 89168221

  172. d'Arville,C.N., Nouri-Aria,K.T., Johnson,P., and Williams,R. (1991). Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 13, 310-315. NLM: 91139063

  173. Lamas,E., Le Bail,B., Housset,C., Boucher,O., and Brechot,C. (1991). Localization of insulin-like growth factor-II and hepatitis B virus mRNAs and proteins in human hepatocellular carcinomas. Lab Invest 64, 98-104. NLM: 91116837

  174. Li,X., Nong,Z., Ekstrom,C., Larsson,E., Nordlinder,H., Hofmann,W.J., Trautwein,C., Odenthal,M., Dienes,H.P., Ekstrom,T.J., and Schirmacher,P. (1997). Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res. 57, 2048-2054. NLM: 97301603

  175. Sohda,T., Oka,Y., Iwata,K., Gunn,J., Kamimura,S., Shijo,H., Okumura,M., and Yun,K. (1997). Co-localisation of insulin-like growth factor II and the proliferation marker MIB1 in hepatocellular carcinoma cells. J. Clin. Pathol. 50, 135-137. NLM: 97300674

  176. Daughaday,W.H., Wu,J.C., Lee,S.D., and Kapadia,M. (1990). Abnormal processing of pro-IGF-II in patients with hepatoma and in some hepatitis B virus antibody-positive asymptomatic individuals. J. Lab Clin. Med. 116, 555-562. NLM: 91011137

  177. Davies,S.M. (1994). Developmental regulation of genomic imprinting of the IGF2 gene in human liver. Cancer Res. 54, 2560-2562. NLM: 94221578

  178. Ekstrom,T.J., Cui,H., Li,X., and Ohlsson,R. (1995). Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 121, 309-316. NLM: 95285754

  179. Li,X., Cui,H., Sandstedt,B., Nordlinder,H., Larsson,E., and Ekstrom,T.J. (1996). Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. J. Endocrinol. 149, 117-124. NLM: 96256167

  180. Lustig,O., Ariel,I., Ilan,J., Lev-Lehman,E., De Groot,N., and Hochberg,A. (1994). Expression of the imprinted gene H19 in the human fetus. Mol. Reprod. Dev. 38, 239-246. NLM: 95000639

  181. Nardone,G., Romano,M., Calabro,A., Pedone,P.V., de,S., I, Persico,M., Budillon,G., Bruni,C.B., Riccio,A., and Zarrilli,R. (1996). Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 23, 1304-1312. NLM: 96243145

  182. Ariel,I., Miao,H.Q., Ji,X.R., Schneider,T., Roll,D., De Groot,N., Hochberg,A., and Ayesh,S. (1998). Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol. Pathol. 51, 21-25. NLM: 98287498

  183. Sohda,T., Iwata,K., Soejima,H., Kamimura,S., Shijo,H., and Yun,K. (1998). In situ detection of insulin-like growth factor II (IGF2) and H19 gene expression in hepatocellular carcinoma. J. Hum. Genet. 43, 49-53. NLM: 98272918

  184. Aihara,T., Noguchi,S., Miyoshi,Y., Nakano,H., Sasaki,Y., Nakamura,Y., Monden,M., and Imaoka,S. (1998). Allelic imbalance of insulin-like growth factor II gene expression in cancerous and precancerous lesions of the liver. Hepatology 28, 86-89. NLM: 98319182

  185. Kim,K.S. and Lee,Y.I. (1997). Biallelic expression of the H19 and IGF2 genes in hepatocellular carcinoma. Cancer Lett. 119, 143-148. NLM: 98230290

  186. Takeda,S., Kondo,M., Kumada,T., Koshikawa,T., Ueda,R., Nishio,M., Osada,H., Suzuki,H., Nagatake,M., Washimi,O., Takagi,K., Takahashi,T., Nakao,A., and Takahashi,T. (1996). Allelic-expression imbalance of the insulin-like growth factor 2 gene in hepatocellular carcinoma and underlying disease. Oncogene 12, 1589-1592. NLM: 96204016

  187. Uchida,K., Kondo,M., Takeda,S., Osada,H., Takahashi,T., Nakao,A., and Takahashi,T. (1997). Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol. Carcinog. 18, 193-198. NLM: 97287121

  188. Kondoh,N., Wakatsuki,T., Ryo,A., Hada,A., Aihara,T., Horiuchi,S., Goseki,N., Matsubara,O., Takenaka,K., Shichita,M., Tanaka,K., Shuda,M., and Yamamoto,M. (1999). Identification and characterization of genes associated with human hepatocellular carcinogenesis. Cancer Res. 59, 4990-4996. NLM: 99446902

  189. Donaghy,A., Ross,R., Gimson,A., Hughes,S.C., Holly,J., and Williams,R. (1995). Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology 21, 680-688. NLM: 95180827

  190. Sue,S.R., Chari,R.S., Kong,F.M., Mills,J.J., Fine,R.L., Jirtle,R.L., and Meyers,W.C. (1995). Transforming growth factor-beta receptors and mannose 6- phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann. Surg. 222, 171-178. NLM: 95366825

  191. De Souza,A.T., Hankins,G.R., Washington,M.K., Fine,R.L., Orton,T.C., and Jirtle,R.L. (1995). Frequent loss of heterozygosity on 6q at the mannose 6- phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10, 1725-1729. NLM: 95273088

  192. Piao,Z., Choi,Y., Park,C., Lee,W.J., Park,J.H., and Kim,H. (1997). Deletion of the M6P/IGF2r gene in primary hepatocellular carcinoma. Cancer Lett. 120, 39-43. NLM: 98230310

  193. Yamada,T., De Souza,A.T., Finkelstein,S., and Jirtle,R.L. (1997). Loss of the gene encoding mannose 6-phosphate/insulin-like growth factor II receptor is an early event in liver carcinogenesis. Proc. Natl. Acad. Sci. U. S. A 94, 10351-10355. NLM: 97439868

  194. Wada,I., Kanada,H., Nomura,K., Kato,Y., Machinami,R., and Kitagawa,T. (1999). Failure to detect genetic alteration of the mannose-6-phosphate/insulin- like growth factor 2 receptor (M6P/IGF2R) gene in hepatocellular carcinomas in Japan. Hepatology 29, 1718-1721. NLM: 99278285

  195. De Souza,A.T., Hankins,G.R., Washington,M.K., Orton,T.C., and Jirtle,R.L. (1995). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat. Genet. 11, 447-449. NLM: 96083596

  196. Chang,T.C., Lin,J.J., Yu,S.C., and Chang,T.J. (1990). Absence of growth-hormone receptor in hepatocellular carcinoma and cirrhotic liver. Hepatology 11, 123-126. NLM: 90109029

  197. Ljubimova,J.Y., Petrovic,L.M., Wilson,S.E., Geller,S.A., and Demetriou,A.A. (1997). Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J. Histochem. Cytochem. 45, 79-87. NLM: 97163665

  198. Okano,J., Shiota,G., and Kawasaki,H. (1999). Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 19, 151-159. NLM: 99237095

  199. Yoshinaga,Y., Matsuno,Y., Fujita,S., Nakamura,T., Kikuchi,M., Shimosato,Y., and Hirohashi,S. (1993). Immunohistochemical detection of hepatocyte growth factor/scatter factor in human cancerous and inflammatory lesions of various organs. Jpn. J. Cancer Res. 84, 1150-1158. NLM: 94103109

  200. D'Errico,A., Fiorentino,M., Ponzetto,A., Daikuhara,Y., Tsubouchi,H., Brechot,C., Scoazec,J.Y., and Grigioni,W.F. (1996). Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: its specific receptor c-met does. Hepatology 24, 60-64. NLM: 96317607

  201. Ueki,T., Fujimoto,J., Suzuki,T., Yamamoto,H., and Okamoto,E. (1997). Expression of hepatocyte growth factor and its receptor c-met proto- oncogene in hepatocellular carcinoma. Hepatology 25, 862-866. NLM: 97250906

  202. Noguchi,O., Enomoto,N., Ikeda,T., Kobayashi,F., Marumo,F., and Sato,C. (1996). Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. J. Hepatol. 24, 286-292. NLM: 96265225

  203. Selden,C., Farnaud,S., Ding,S.F., Habib,N., Foster,C., and Hodgson,H.J. (1994). Expression of hepatocyte growth factor mRNA, and c-met mRNA (hepatocyte growth factor receptor) in human liver tumours. J. Hepatol. 21, 227-234. NLM: 95081554

  204. Ho,R.T., Liew,C.T., and Lai,K.N. (1999). The expression of hepatocyte growth factor (HGF) and interleukin 6 (IL- 6) in damaged human liver and kidney tissues. Hepatogastroenterology 46, 1904-1909. NLM: 99357436

  205. Shiota,G., Okano,J., Kawasaki,H., Kawamoto,T., and Nakamura,T. (1995). Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 21, 106-112. NLM: 95104747

  206. Chen,Q., Seol,D.W., Carr,B., and Zarnegar,R. (1997). Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology 26, 59-66. NLM: 97357101

  207. Di Renzo,M.F., Narsimhan,R.P., Olivero,M., Bretti,S., Giordano,S., Medico,E., Gaglia,P., Zara,P., and Comoglio,P.M. (1991). Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 6, 1997-2003. NLM: 92050795

  208. Prat,M., Narsimhan,R.P., Crepaldi,T., Nicotra,M.R., Natali,P.G., and Comoglio,P.M. (1991). The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int. J. Cancer 49, 323-328. NLM: 92010340

  209. Boix,L., Rosa,J.L., Ventura,F., Castells,A., Bruix,J., Rodes,J., and Bartrons,R. (1994). c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19, 88-91. NLM: 94102713

  210. Suzuki,K., Hayashi,N., Yamada,Y., Yoshihara,H., Miyamoto,Y., Ito,Y., Ito,T., Katayama,K., Sasaki,Y., Ito,A., and . (1994). Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20, 1231-1236. NLM: 95012139

  211. Grigioni,W.F., Fiorentino,M., D'Errico,A., Ponzetto,A., Crepaldi,T., Prat,M., and Comoglio,P.M. (1995). Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology 21, 1543-1546. NLM: 95286137

  212. Park,W.S., Dong,S.M., Kim,S.Y., Na,E.Y., Shin,M.S., Pi,J.H., Kim,B.J., Bae,J.H., Hong,Y.K., Lee,K.S., Lee,S.H., Yoo,N.J., Jang,J.J., Pack,S., Zhuang,Z., Schmidt,L., Zbar,B., and Lee,J.Y. (1999). Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 59, 307-310. NLM: 99124227

  213. Bevilacqua,M., Norbiato,G., Chebat,E., Baldi,G., Bertora,P., Regalia,E., Colella,G., Gennari,L., and Vago,T. (1991). Changes in alpha-1 and beta-2 adrenoceptor density in human hepatocellular carcinoma. Cancer 67, 2543-2551. NLM: 91199023

  214. Motoo,Y., Sawabu,N., Yamaguchi,Y., Terada,T., and Nakanuma,Y. (1993). Sinusoidal capillarization of human hepatocellular carcinoma: possible promotion by fibroblast growth factor. Oncology 50, 270-274. NLM: 93268478

  215. Shimoyama,Y., Gotoh,M., Ino,Y., Sakamoto,M., Kato,K., and Hirohashi,S. (1991). Characterization of high-molecular-mass forms of basic fibroblast growth factor produced by hepatocellular carcinoma cells: possible involvement of basic fibroblast growth factor in hepatocarcinogenesis. Jpn. J. Cancer Res. 82, 1263-1270. NLM: 92091228

  216. Li,D., Bell,J., Brown,A., and Berry,C.L. (1994). The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J. Pathol. 172, 171-175. NLM: 94223448

  217. Mise,M., Arii,S., Higashituji,H., Furutani,M., Niwano,M., Harada,T., Ishigami,S., Toda,Y., Nakayama,H., Fukumoto,M., Fujita,J., and Imamura,M. (1996). Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23, 455-464. NLM: 96206101

  218. Tsou,A.P., Wu,K.M., Tsen,T.Y., Chi,C.W., Chiu,J.H., Lui,W.Y., Hu,C.P., Chang,C., Chou,C.K., and Tsai,S.F. (1998). Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 50, 331-340. NLM: 98341116

  219. Chow,N.H., Hsu,P.I., Lin,X.Z., Yang,H.B., Chan,S.H., Cheng,K.S., Huang,S.M., and Su,I.J. (1997). Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum. Pathol. 28, 698-703. NLM: 97334307

  220. Torimura,T., Sata,M., Ueno,T., Kin,M., Tsuji,R., Suzaku,K., Hashimoto,O., Sugawara,H., and Tanikawa,K. (1998). Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum. Pathol. 29, 986-991. NLM: 98415565

  221. Yamaguchi,R., Yano,H., Iemura,A., Ogasawara,S., Haramaki,M., and Kojiro,M. (1998). Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28, 68-77. NLM: 98319180

  222. Kobayashi,N., Ishii,M., Ueno,Y., Kisara,N., Chida,N., Iwasaki,T., and Toyota,T. (1999). Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19, 25-31. NLM: 99125842

  223. Zhou,J., Tang,Z.Y., Fan,J., Wu,Z.Q., Li,X.M., Liu,Y.K., Liu,F., Sun,H.C., and Ye,S.L. (2000). Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J. Cancer Res. Clin. Oncol. 126, 57-61. NLM: 20104717

  224. Suzuki,K., Hayashi,N., Miyamoto,Y., Yamamoto,M., Ohkawa,K., Ito,Y., Sasaki,Y., Yamaguchi,Y., Nakase,H., Noda,K., Enomoto,N., Arai,K., Yamada,Y., Yoshihara,H., Tujimura,T., Kawano,K., Yoshikawa,K., and Kamada,T. (1996). Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. 56, 3004-3009. NLM: 96258224

  225. Li,X.M., Tang,Z.Y., Zhou,G., Lui,Y.K., and Ye,S.L. (1998). Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 17, 13-17. NLM: 98310196

  226. Shimoda,K., Mori,M., Shibuta,K., Banner,B.F., and Barnard,G.F. (1999). Vascular endothelial growth factor/vascular permeability factor mRNA expression in patients with chronic hepatitis C and hepatocellular carcinoma. Int. J. Oncol. 14, 353-359. NLM: 99117540

  227. Jin-no,K., Tanimizu,M., Hyodo,I., Nishikawa,Y., Hosokawa,Y., Endo,H., Doi,T., Mandai,K., and Ishitsuka,H. (1998). Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer 82, 1260-1267. NLM: 98187866

  228. Milani,S., Herbst,H., Schuppan,D., Stein,H., and Surrenti,C. (1991). Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am. J. Pathol. 139, 1221-1229. NLM: 92087864

  229. Bedossa,P., Peltier,E., Terris,B., Franco,D., and Poynard,T. (1995). Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21, 760-766. NLM: 95180839

  230. Orsatti,G., Hytiroglou,P., Thung,S.N., Ishak,K.G., and Paronetto,F. (1997). Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver 17, 152-156. NLM: 97393213

  231. Nagy,P., Schaff,Z., and Lapis,K. (1991). Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. Hepatology 14, 269-273. NLM: 91317500

  232. Annoni,G., Weiner,F.R., and Zern,M.A. (1992). Increased transforming growth factor-beta 1 gene expression in human liver disease. J. Hepatol. 14, 259-264. NLM: 92364268

  233. Roulot,D., Durand,H., Coste,T., Rautureau,J., Strosberg,A.D., Benarous,R., and Marullo,S. (1995). Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology 21, 298-304. NLM: 95146028

  234. Takiya,S., Tagaya,T., Takahashi,K., Kawashima,H., Kamiya,M., Fukuzawa,Y., Kobayashi,S., Fukatsu,A., Katoh,K., and Kakumu,S. (1995). Role of transforming growth factor beta 1 on hepatic regeneration and apoptosis in liver diseases. J. Clin. Pathol. 48, 1093-1097. NLM: 96165051

  235. Ito,N., Kawata,S., Tamura,S., Takaishi,K., Yabuuchi,I., Matsuda,Y., Nishioka,M., and Tarui,S. (1990). Expression of transforming growth factor-beta 1 mRNA in human hepatocellular carcinoma. Jpn. J. Cancer Res. 81, 1202-1205. NLM: 91115656

  236. Ito,N., Kawata,S., Tamura,S., Takaishi,K., Shirai,Y., Kiso,S., Yabuuchi,I., Matsuda,Y., Nishioka,M., and Tarui,S. (1991). Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res. 51, 4080-4083. NLM: 91309094

  237. Abou-Shady,M., Baer,H.U., Friess,H., Berberat,P., Zimmermann,A., Graber,H., Gold,L.I., Korc,M., and Buchler,M.W. (1999). Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am. J. Surg. 177, 209-215. NLM: 99235262

  238. Shirai,Y., Kawata,S., Ito,N., Tamura,S., Takaishi,K., Kiso,S., Tsushima,H., and Matsuzawa,Y. (1992). Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn. J. Cancer Res. 83, 676-679. NLM: 92388001

  239. Shirai,Y., Kawata,S., Tamura,S., Ito,N., Tsushima,H., Takaishi,K., Kiso,S., and Matsuzawa,Y. (1994). Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73, 2275-2279. NLM: 94221522

  240. Ito,N., Kawata,S., Tamura,S., Shirai,Y., Kiso,S., Tsushima,H., and Matsuzawa,Y. (1995). Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett. 89, 45-48. NLM: 95188134

  241. Tsai,J.F., Chuang,L.Y., Jeng,J.E., Yang,M.L., Chang,W.Y., Hsieh,M.Y., Lin,Z.Y., and Tsai,J.H. (1997). Clinical relevance of transforming growth factor-beta 1 in the urine of patients with hepatocellular carcinoma. Medicine (Baltimore) 76, 213-226. NLM: 97336709

  242. Vincent,F., Hagiwara,K., Ke,Y., Stoner,G.D., Demetrick,D.J., and Bennett,W.P. (1996). Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem. Biophys. Res. Commun. 223, 561-564. NLM: 96268718

  243. Kawate,S., Takenoshita,S., Ohwada,S., Mogi,A., Fukusato,T., Makita,F., Kuwano,H., and Morishita,Y. (1999). Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int. J. Oncol. 14, 127-131. NLM: 99081915

  244. Salvucci,M., Lemoine,A., Saffroy,R., Azoulay,D., Lepere,B., Gaillard,S., Bismuth,H., Reynes,M., and Debuire,B. (1999). Microsatellite instability in European hepatocellular carcinoma. Oncogene 18, 181-187. NLM: 99124123

  245. Furuta,K., Misao,S., Takahashi,K., Tagaya,T., Fukuzawa,Y., Ishikawa,T., Yoshioka,K., and Kakumu,S. (1999). Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int. J. Cancer 81, 851-853. NLM: 99288974

  246. Adami,H.O., Chow,W.H., Nyren,O., Berne,C., Linet,M.S., Ekbom,A., Wolk,A., McLaughlin,J.K., and Fraumeni,J.F., Jr. (1996). Excess risk of primary liver cancer in patients with diabetes mellitus. J. Natl. Cancer Inst. 88, 1472-1477. NLM: 96438662

  247. Nishiyama,M. and Wands,J.R. (1992). Cloning and increased expression of an insulin receptor substrate-1- like gene in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 183, 280-285. NLM: 92181456

  248. Furusaka,A., Nishiyama,M., Ohkawa,K., Yamori,T., Tsuruo,T., Yonezawa,K., Kasuga,M., Hayashi,S., and Tanaka,T. (1994). Expression of insulin receptor substrate-1 in hepatocytes: an investigation using monoclonal antibodies. Cancer Lett. 84, 85-92. NLM: 94356883

  249. Tanaka,S., Mohr,L., Schmidt,E.V., Sugimachi,K., and Wands,J.R. (1997). Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 26, 598-604. NLM: 97447748

  250. Lin,K.H., Shieh,H.Y., Chen,S.L., and Hsu,H.C. (1999). Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol. Carcinog. 26, 53-61. NLM: 99415463

  251. Lin,K.H., Zhu,X.G., Hsu,H.C., Chen,S.L., Shieh,H.Y., Chen,S.T., McPhie,P., and Cheng,S.Y. (1997). Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma. Endocrinology 138, 5308-5315. NLM: 98049383

  252. Lin,K.H., Lin,Y.W., Lee,H.F., Liu,W.L., Chen,S.T., Chang,K.S., and Cheng,S.Y. (1995). Increased invasive activity of human hepatocellular carcinoma cells is associated with an overexpression of thyroid hormone beta 1 nuclear receptor and low expression of the anti-metastatic nm23 gene. Cancer Lett. 98, 89-95. NLM: 96128103

  253. Nelson,R.B. (1979). Thyroxine-binding globulin in hepatoma. Arch. Intern. Med. 139, 1063. NLM: 79254873

  254. Kalk,W.J., Kew,M.C., Danilewitz,M.D., Jacks,F., van der Walt,L.A., and Levin,J. (1982). Thyroxine binding globulin and thyroid function tests in patients with hepatocellular carcinoma. Hepatology 2, 72-76. NLM: 82096739

  255. Alexopoulos,A., Hutchinson,W., Bari,A., Keating,J.J., Johnson,P.J., and Williams,R. (1988). Hyperthyroxinaemia in hepatocellular carcinoma: relation to thyroid binding globulin in the clinical and preclinical stages of the disease. Br. J. Cancer 57, 313-316. NLM: 88183929

  256. Hutchinson,W.L., Johnson,P.J., White,Y.S., and Williams,R. (1989). Differential hormone-binding characteristics of thyroxine-binding globulin in hepatocellular carcinoma and cirrhosis. J. Hepatol. 9, 265-271. NLM: 90038373

  257. Hutchinson,W.L., White,Y.S., Fagan,E.A., Johnson,P.J., and Williams,R. (1991). Impaired binding properties of thyroxine-binding globulin in hepatocellular carcinoma and chronic liver disease. Hepatology 14, 116-120. NLM: 91293708

  258. Arbuthnot,P., Kew,M., Parker,I., and Fitschen,W. (1989). Expression of c-erbA in human hepatocellular carcinomas. Anticancer Res. 9, 885-887. NLM: 90055031

  259. Guechot,J., Peigney,N., Ballet,F., Vaubourdolle,M., Giboudeau,J., and Poupon,R. (1988). Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer 62, 760-762. NLM: 88282303

  260. Yu,M.W. and Chen,C.J. (1993). Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 53, 790-794. NLM: 93153774

  261. Guechot,J., Peigney,N., Ballet,F., Vaubourdolle,M., Giboudeau,J., and Poupon,R. (1989). Effect of D-tryptophan-6-luteinizing hormone-releasing hormone on the tumoral growth and plasma sex steroid levels in cirrhotic patients with hepatocellular carcinoma. Hepatology 10, 346-348. NLM: 89339404

  262. Hsing,A.W., Hoover,R.N., McLaughlin,J.K., Co-Chien,H.T., Wacholder,S., Blot,W.J., and Fraumeni,J.F., Jr. (1992). Oral contraceptives and primary liver cancer among young women. Cancer Causes Control 3, 43-48. NLM: 92162963

  263. Sweeney,E.C. and Evans,D.J. (1976). Hepatic lesions in patients treated with synthetic anabolic steriods. J. Clin. Pathol. 29, 626-633. NLM: 77029294

  264. Boyd,P.R. and Mark,G.J. (1977). Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for eleven years. Cancer 40, 1765-1770. NLM: 78001675

  265. Iqbal,M.J., Wilkinson,M.L., Johnson,P.J., and Williams,R. (1983). Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. Br. J. Cancer 48, 791-796. NLM: 84080271

  266. Nagasue,N., Ito,A., Yukaya,H., and Ogawa,Y. (1985). Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology 89, 643-647. NLM: 85258853

  267. Eagon,P.K., Francavilla,A., DiLeo,A., Elm,M.S., Gennari,L., Mazzaferro,V., Colella,G., Van Thiel,D.H., and Strazl,T.E. (1991). Quantitation of estrogen and androgen receptors in hepatocellular carcinoma and adjacent normal human liver. Dig. Dis. Sci. 36, 1303-1308. NLM: 91372060

  268. Eagon,P.K., Elm,M.S., Stafford,E.A., and Porter,L.E. (1994). Androgen receptor in human liver: characterization and quantitation in normal and diseased liver. Hepatology 19, 92-100. NLM: 94102714

  269. Nakagama,H., Gunji,T., Ohnishi,S., Kaneko,T., Ishikawa,T., Makino,R., Hayashi,K., Shiga,J., Takaku,F., and Imawari,M. (1991). Expression of androgen receptor mRNA in human hepatocellular carcinomas and hepatoma cell lines. Hepatology 14, 99-102. NLM: 91293738

  270. Nagasue,N., Yukaya,H., Chang,Y.C., Ogawa,Y., Kohno,H., and Ito,A. (1986). Active uptake of testosterone by androgen receptors of hepatocellular carcinoma in humans. Cancer 57, 2162-2167. NLM: 86189415

  271. Nagasue,N., Yamanoi,A., Kohno,H., Kimoto,T., Chang,Y., Taniura,H., Uchida,M., and Nakamura,T. (1992). Androgen receptor in cirrhotic liver, adenomatous hyperplastic nodule and hepatocellular carcinoma in the human. Hepatogastroenterology 39, 455-460. NLM: 93093562

  272. Ohnishi,S., Murakami,T., Moriyama,T., Mitamura,K., and Imawari,M. (1986). Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology 6, 440-443. NLM: 86222201

  273. Nagasue,N., Chang,Y.C., Hayashi,T., Galizia,G., Kohno,H., Nakamura,T., and Yukaya,H. (1989). Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann. Surg. 209, 424-427. NLM: 89192590

  274. Nagasue,N., Kohno,H., Chang,Y.C., Hayashi,T., Utsumi,Y., Nakamura,T., and Yukaya,H. (1989). Androgen and estrogen receptors in hepatocellular carcinoma and the surrounding liver in women. Cancer 63, 112-116. NLM: 89089486

  275. Nagasue,N., Yu,L., Yukaya,H., Kohno,H., and Nakamura,T. (1995). Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br. J. Surg. 82, 542-547. NLM: 95338642

  276. Boix,L., Bruix,J., Castells,A., Fuster,J., Bru,C., Visa,J., Rivera,F., and Rodes,J. (1993). Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J. Hepatol. 17, 187-191. NLM: 93187328

  277. Boix,L., Castells,A., Bruix,J., Sole,M., Bru,C., Fuster,J., Rivera,F., and Rodes,J. (1995). Androgen receptors in hepatocellular carcinoma and surrounding liver: relationship with tumor size and recurrence rate after surgical resection. J. Hepatol. 22, 616-622. NLM: 96035136

  278. Zhang,X., He,L., Lu,Y., Liu,M., and Huang,X. (1998). Androgen receptor in primary hepatocellular carcinoma and its clinical significance. Chin Med. J. (Engl. ) 111, 1083-1086. NLM: 21161900

  279. Porter,L.E., Elm,M.S., Van Thiel,D.H., Dugas,M.C., and Eagon,P.K. (1983). Characterization and quantitation of human hepatic estrogen receptor. Gastroenterology 84, 704-712. NLM: 83133076

  280. Porter,L.E., Elm,M.S., Van Thiel,D.H., and Eagon,P.K. (1987). Hepatic estrogen receptor in human liver disease. Gastroenterology 92, 735-745. NLM: 87134856

  281. Nagasue,N., Ito,A., Yukaya,H., and Ogawa,Y. (1986). Estrogen receptors in hepatocellular carcinoma. Cancer 57, 87-91. NLM: 86079071

  282. Ciocca,D.R., Jorge,A.D., Jorge,O., Milutin,C., Hosokawa,R., Diaz,L.M., Muzzio,E., Schulkin,S., and Schirbu,R. (1991). Estrogen receptors, progesterone receptors and heat-shock 27-kD protein in liver biopsy specimens from patients with hepatitis B virus infection. Hepatology 13, 838-844. NLM: 91231246

  283. Nagasue,N., Kohno,H., Chang,Y.C., Yamanoi,A., Nakamura,T., Yukaya,H., and Hayashi,T. (1990). Clinicopathologic comparisons between estrogen receptor-positive and - negative hepatocellular carcinomas. Ann. Surg. 212, 150-154. NLM: 90328784

  284. Villa,E., Camellini,L., Dugani,A., Zucchi,F., Grottola,A., Merighi,A., Buttafoco,P., Losi,L., and Manenti,F. (1995). Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res. 55, 498-500. NLM: 95136220

  285. Villa,E., Dugani,A., Moles,A., Camellini,L., Grottola,A., Buttafoco,P., Merighi,A., Ferretti,I., Esposito,P., Miglioli,L., Bagni,A., Troisi,R., De Hemptinne,B., Praet,M., Callea,F., and Manenti,F. (1998). Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 27, 983-988. NLM: 98196784

  286. Carbone,A. and Vecchio,F.M. (1986). Presence of cytoplasmic progesterone receptors in hepatic adenomas. A report of two cases. Am. J. Clin. Pathol. 85, 325-329. NLM: 86320073

  287. Nagasue,N., Kohno,H., Yamanoi,A., Kimoto,T., Chang,Y.C., and Nakamura,T. (1991). Progesterone receptor in hepatocellular carcinoma. Correlation with androgen and estrogen receptors. Cancer 67, 2501-2505. NLM: 91199016

  288. Petkovich,M., Brand,N.J., Krust,A., and Chambon,P. (1987). A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 330, 444-450. NLM: 88065872

  289. de The,H., Marchio,A., Tiollais,P., and Dejean,A. (1989). Differential expression and ligand regulation of the retinoic acid receptor alpha and beta genes. EMBO J. 8, 429-433. NLM: 89251568

  290. Dejean,A., Bougueleret,L., Grzeschik,K.H., and Tiollais,P. (1986). Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature 322, 70-72. NLM: 86257411

  291. de The,H., Marchio,A., Tiollais,P., and Dejean,A. (1987). A novel steroid thyroid hormone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 330, 667-670. NLM: 88065931

  292. Brand,N., Petkovich,M., Krust,A., Chambon,P., de The,H., Marchio,A., Tiollais,P., and Dejean,A. (1988). Identification of a second human retinoic acid receptor. Nature 332, 850-853. NLM: 88189352

  293. Benbrook,D., Lernhardt,E., and Pfahl,M. (1988). A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature 333, 669-672. NLM: 88232961

  294. Krust,A., Kastner,P., Petkovich,M., Zelent,A., and Chambon,P. (1989). A third human retinoic acid receptor, hRAR-gamma. Proc. Natl. Acad. Sci. U. S. A 86, 5310-5314. NLM: 89315787

  295. Sever,C.E. and Locker,J. (1991). Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol. Carcinog. 4, 138-144. NLM: 91254497

  296. Reubi,J.C., Zimmermann,A., Jonas,S., Waser,B., Neuhaus,P., Laderach,U., and Wiedenmann,B. (1999). Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45, 766-774. NLM: 99447691

  297. Caplin,M., Khan,K., Savage,K., Rode,J., Varro,A., Michaeli,D., Grimes,S., Brett,B., Pounder,R., and Dhillon,A. (1999). Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J. Hepatol. 30, 519-526. NLM: 99205013

  298. Nonomura,A., Ohta,G., Hayashi,M., Izumi,R., Watanabe,K., Takayanagi,N., Mizukami,Y., and Matsubara,F. (1987). Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am. J. Gastroenterol. 82, 512-518. NLM: 87210042

  299. Lee,H.S., Rajagopalan,M.S., and Vyas,G.N. (1988). A lack of direct role of hepatitis B virus in the activation of ras and c-myc oncogenes in human hepatocellular carcinogenesis. Hepatology 8, 1116-1120. NLM: 88329949

  300. Jagirdar,J., Nonomura,A., Patil,J., Thor,A., and Paronetto,F. (1989). ras oncogene p21 expression in hepatocellular carcinoma. J. Exp. Pathol. 4, 37-46. NLM: 89381916

  301. Tiniakos,D., Spandidos,D.A., Kakkanas,A., Pintzas,A., Pollice,L., and Tiniakos,G. (1989). Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues. Anticancer Res. 9, 715-721. NLM: 89350081

  302. Tiniakos,D., Spandidos,D.A., Yiagnisis,M., and Tiniakos,G. (1993). Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease. Hepatogastroenterology 40, 37-40. NLM: 93216207

  303. Radosevich,J.A., Gould,K.A., Koukoulis,G.K., Haines,G.K., Rosen,S.T., Lee,I., and Gould,V.E. (1993). Immunolocalization of ras oncogene p21 in human liver diseases. Ultrastruct. Pathol. 17, 1-8. NLM: 93150566

  304. Haritani,H., Esumi,M., Uchida,T., and Shikata,T. (1991). Oncogene expression in the liver tissue of patients with nonneoplastic liver disease. Cancer 67, 2594-2598. NLM: 91199029

  305. Zhang,X.K., Huang,D.P., Chiu,D.K., and Chiu,J.F. (1987). The expression of oncogenes in human developing liver and hepatomas. Biochem. Biophys. Res. Commun. 142, 932-938. NLM: 87156718

  306. Himeno,Y., Fukuda,Y., Hatanaka,M., and Imura,H. (1988). Expression of oncogenes in human liver disease. Liver 8, 208-212. NLM: 88334162

  307. Gu,J.R., Hu,L.F., Cheng,Y.C., and Wan,D.F. (1986). Oncogenes in human primary hepatic cancer. J. Cell Physiol Suppl 4:13-20., 13-20. NLM: 86304599

  308. Zhang,X.K., Huang,D.P., Qiu,D.K., and Chiu,J.F. (1990). The expression of c-myc and c-N-ras in human cirrhotic livers, hepatocellular carcinomas and liver tissue surrounding the tumors. Oncogene 5, 909-914. NLM: 90295286

  309. Ogata,N., Kamimura,T., and Asakura,H. (1991). Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 13, 31-37. NLM: 91106962

  310. Fukuda,K., Ogasawara,S., Maruiwa,M., Yano,H., Murakami,T., and Kojiro,M. (1988). Structural alterations in c-myc and c-Ha-ras proto-oncogenes in human hepatocellular carcinoma. Kurume Med. J. 35, 77-87. NLM: 89056241

  311. Tada,M., Omata,M., and Ohto,M. (1990). Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 50, 1121-1124. NLM: 90124317

  312. Challen,C., Guo,K., Collier,J.D., Cavanagh,D., and Bassendine,M.F. (1992). Infrequent point mutations in codons 12 and 61 of ras oncogenes in human hepatocellular carcinomas. J. Hepatol. 14, 342-346. NLM: 92364281

  313. Kress,S., Jahn,U.R., Buchmann,A., Bannasch,P., and Schwarz,M. (1992). p53 Mutations in human hepatocellular carcinomas from Germany. Cancer Res. 52, 3220-3223. NLM: 92274386

  314. Leon,M. and Kew,M.C. (1995). Analysis of ras gene mutations in hepatocellular carcinoma in southern African blacks. Anticancer Res. 15, 859-861. NLM: 95373946

  315. Tsuda,H., Hirohashi,S., Shimosato,Y., Ino,Y., Yoshida,T., and Terada,M. (1989). Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human hepatocellular carcinoma. Jpn. J. Cancer Res. 80, 196-199. NLM: 89254792

  316. Stork,P., Loda,M., Bosari,S., Wiley,B., Poppenhusen,K., and Wolfe,H. (1991). Detection of K-ras mutations in pancreatic and hepatic neoplasms by non- isotopic mismatched polymerase chain reaction. Oncogene 6, 857-862. NLM: 91270905

  317. Imai,Y., Oda,H., Arai,M., Shimizu,S., Nakatsuru,Y., Inoue,T., and Ishikawa,T. (1996). Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn. J. Cancer Res. 87, 1056-1062. NLM: 97115972

  318. Takada,S. and Koike,K. (1989). Activated N-ras gene was found in human hepatoma tissue but only in a small fraction of the tumor cells. Oncogene 4, 189-193. NLM: 89183153

  319. Schmidt,C.M., McKillop,I.H., Cahill,P.A., and Sitzmann,J.V. (1997). Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236, 54-58. NLM: 97366595

  320. Ito,Y., Sasaki,Y., Horimoto,M., Wada,S., Tanaka,Y., Kasahara,A., Ueki,T., Hirano,T., Yamamoto,H., Fujimoto,J., Okamoto,E., Hayashi,N., and Hori,M. (1998). Activation of mitogen-activated protein kinases/extracellular signal- regulated kinases in human hepatocellular carcinoma. Hepatology 27, 951-958. NLM: 98196780

  321. Masaki,T., Okada,M., Shiratori,Y., Rengifo,W., Matsumoto,K., Maeda,S., Kato,N., Kanai,F., Komatsu,Y., Nishioka,M., and Omata,M. (1998). pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 27, 1257-1264. NLM: 98240811

  322. Schmidt,C.M., McKillop,I.H., Cahill,P.A., and Sitzmann,J.V. (1997). Alterations in guanine nucleotide regulatory protein expression and activity in human hepatocellular carcinoma. Hepatology 26, 1189-1194. NLM: 98026684

  323. Arbuthnot,P., Kew,M., and Fitschen,W. (1991). c-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res. 11, 921-924. NLM: 91290777

  324. Gan,F.Y., Gesell,M.S., Alousi,M., and Luk,G.D. (1993). Analysis of ODC and c-myc gene expression in hepatocellular carcinoma by in situ hybridization and immunohistochemistry. J. Histochem. Cytochem. 41, 1185-1196. NLM: 93322598

  325. Saegusa,M., Takano,Y., Kishimoto,H., Wakabayashi,G., Nohga,K., and Okudaira,M. (1993). Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach. J. Cancer Res. Clin. Oncol. 119, 737-744. NLM: 94012931

  326. Su,T.S., Lin,L.H., Lui,W.Y., Chang,C.M., Chou,C.K., Ting,L.P., Hu,C.P., Han,S.H., and P'eng,F.K. (1985). Expression of c-myc gene in human hepatoma. Biochem. Biophys. Res. Commun. 132, 264-268. NLM: 86050586

  327. Nambu,S., Inoue,K., and Saski,H. (1987). Site-specific hypomethylation of the c-myc oncogene in human hepatocellular carcinoma. Jpn. J. Cancer Res. 78, 695-704. NLM: 87307644

  328. Fujiwara,Y., Monden,M., Mori,T., Nakamura,Y., and Emi,M. (1993). Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res. 53, 857-860. NLM: 93153785

  329. Peng,S.Y., Lai,P.L., and Hsu,H.C. (1993). Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. J. Formos. Med. Assoc. 92, 866-870. NLM: 94198620

  330. Abou-Elella,A., Gramlich,T., Fritsch,C., and Gansler,T. (1996). c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod. Pathol. 9:95-98, 95-988.

  331. Kawate,S., Fukusato,T., Ohwada,S., Watanuki,A., and Morishita,Y. (1999). Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57, 157-163. NLM: 99391881

  332. Taylor,J.A., Bell,D.A., and Nagorney,D. (1993). L-myc proto-oncogene alleles and susceptibility to hepatocellular carcinoma. Int. J. Cancer 54, 927-930. NLM: 93328343

  333. Choi,E.K., Uyeno,S., Nishida,N., Okumoto,T., Fujimura,S., Aoki,Y., Nata,M., Sagisaka,K., Fukuda,Y., Nakao,K., Yoshimoto,T., Kim,Y.S., and Ono,T. (1996). Alterations of c-fos gene methylation in the processes of aging and tumorigenesis in human liver. Mutat. Res. 354, 123-128. NLM: 96305485

  334. Schutte,M., Hruban,R.H., Hedrick,L., Cho,K.R., Nadasdy,G.M., Weinstein,C.L., Bova,G.S., Isaacs,W.B., Cairns,P., Nawroz,H., Sidransky,D., Casero,R.A., Jr., Meltzer,P.S., Hahn,S.A., and Kern,S.E. (1996). DPC4 gene in various tumor types. Cancer Res. 56, 2527-2530.